Paclitaxel Reduces Brain Injury from Repeated Head Trauma in Mice.
Administration, Intranasal
Animals
Brain
/ diagnostic imaging
Brain Concussion
/ diagnostic imaging
Craniocerebral Trauma
/ complications
Diffusion Tensor Imaging
Male
Maze Learning
Mice
Mice, Inbred C57BL
Neuroimaging
Paclitaxel
/ administration & dosage
Tubulin Modulators
/ administration & dosage
beta-Lactamases
Axonal injury
imaging
microtubule-stabilizing drug
repeat mild traumatic
brain injury
synaptic preservation
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
22
1
2019
medline:
30
5
2020
entrez:
22
1
2019
Statut:
ppublish
Résumé
Repetitive mild traumatic brain injury (rmTBI) is known to disturb axonal integrity and may play an important role in the pathogenic cascades leading to neurodegeneration. One critical approach to reduce the future onset of neurodegeneration is to intervene in this process at an early stage following a brain injury. Previously we showed that direct application of the microtubule-stabilizing drug, paclitaxel, on the brain following controlled cortical impact improved motor function and reduced lesion size. Herein, we extended these findings to a model of mild brain injury induced by repeated closed-skull impacts. Paclitaxel was administered intranasally to circumvent its poor transport across the blood-brain barrier. Mice received five mild closed-skull impacts (one per day for five days). Intranasal paclitaxel was administered once only, immediately after the first impact. We found that paclitaxel prevented injury-induced deficits in a spatial memory task in a water tread maze. In vivo magnetic resonance imaging (MRI) and positron emission tomography with 18F-flurodeoxyglucose (FDG-PET) revealed that paclitaxel prevented structural injury and hypometabolism. On MRI, apparent, injury-induced microbleeds were observed in 100% of vehicle-treated rmTBI mice, but not in paclitaxel-treated subjects. FDG-PET revealed a 42% increase in whole brain glucose metabolism in paclitaxel-treated mice as compared to vehicle-treated rmTBI. Immunohistochemistry found reduced evidence of axonal injury and synaptic loss. Our results indicate that intranasal paclitaxel administration imparts neuroprotection against brain injury and cognitive impairment in mice. The results from this study support the idea that microtubule-stabilization strategies hold therapeutic promise in mitigating traumatic brain injury.
Identifiants
pubmed: 30664506
pii: JAD180871
doi: 10.3233/JAD-180871
pmc: PMC7043206
mid: NIHMS1066782
doi:
Substances chimiques
Tubulin Modulators
0
beta-Lactamases
EC 3.5.2.6
beta-lactamase MIR-1, Enterobacter cloacae
EC 3.5.2.6
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
859-874Subventions
Organisme : NIA NIH HHS
ID : R01 AG046619
Pays : United States
Organisme : NICHD NIH HHS
ID : U54 HD083091
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002319
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR000423
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK017047
Pays : United States
Références
Dev Neurosci. 1993;15(3-5):194-206
pubmed: 7805571
J Neuropathol Exp Neurol. 2009 Jul;68(7):709-35
pubmed: 19535999
J Neurochem. 1977 May;28(5):897-916
pubmed: 864466
Traffic. 2004 Jul;5(7):470-7
pubmed: 15180824
Nat Rev Neurosci. 2004 Oct;5(10):771-81
pubmed: 15378037
J Neurosci. 2011 Feb 16;31(7):2688-99
pubmed: 21325537
Neurobiol Dis. 2017 Sep;105:328-335
pubmed: 28012891
Brain Res. 1995 Sep 18;692(1-2):278-82
pubmed: 8548316
Arch Neurol. 2012 Jan;69(1):29-38
pubmed: 21911655
Neurosci Lett. 2017 Aug 10;655:143-150
pubmed: 28663054
J Vis Exp. 2017 Jul 17;(125):
pubmed: 28745642
Epilepsia. 2003;44(s10):2-10
pubmed: 14511388
J Neurotrauma. 2013 Mar 1;30(5):307-23
pubmed: 23252624
J Neurochem. 1966 Aug;13(8):655-69
pubmed: 5950056
Neurol Med Chir (Tokyo). 2017 May 15;57(5):199-209
pubmed: 28381654
Brain Res. 2017 Feb 15;1657:140-147
pubmed: 27923635
Drug Target Insights. 2013 Aug 19;7:27-34
pubmed: 24023511
Eur J Pharmacol. 2010 Sep 1;641(2-3):128-34
pubmed: 20570588
Sci Transl Med. 2016 Jan 13;8(321):321ra6
pubmed: 26764157
Acta Neuropathol. 2000 Aug;100(2):183-8
pubmed: 10963366
Neurosurgery. 2005 Jul;57(1):128-34; discussion 128-34
pubmed: 15987548
J Neurotrauma. 2012 Jan 1;29(1):19-31
pubmed: 21988198
Acta Neuropathol. 2016 Jan;131(1):75-86
pubmed: 26667418
Neurobiol Aging. 2006 Mar;27(3):451-8
pubmed: 15964100
Pharmacol Res. 2011 Apr;63(4):341-51
pubmed: 21163349
J Biol Chem. 2003 Mar 7;278(10):8407-19
pubmed: 12496245
Science. 2011 Feb 18;331(6019):928-31
pubmed: 21273450
J Neurotrauma. 2014 Mar 1;31(5):425-36
pubmed: 24102309
J Neurotrauma. 2015 Nov 15;32(22):1736-50
pubmed: 25915799
J Neuroinflammation. 2008 Sep 15;5:38
pubmed: 18793399
J Neuropathol Exp Neurol. 2015 Oct;74(10):1012-35
pubmed: 26360375
Neuroscientist. 2017 Oct;23(5):567-578
pubmed: 27188455
J Neurosci. 2007 Aug 22;27(34):9169-80
pubmed: 17715353
Neuroimage. 2011 Jan;54 Suppl 1:S76-82
pubmed: 20385245
ACS Chem Neurosci. 2017 Jan 18;8(1):5-7
pubmed: 28095679
Neurosci Lett. 2016 Mar 23;617:207-12
pubmed: 26912192
Front Cell Neurosci. 2014 Feb 10;8:34
pubmed: 24574970
Brain Res. 2015 Aug 27;1618:299-308
pubmed: 26086366
J Neurotrauma. 2010 Jan;27(1):65-76
pubmed: 19761385
Acta Neurochir (Wien). 2016 Jul;158(7):1247-50
pubmed: 27106841
Pathobiol Aging Age Relat Dis. 2013 Oct 04;3:
pubmed: 24106580
Neuropharmacology. 2014 Jan;76 Pt A:175-83
pubmed: 23978385
Proc Natl Acad Sci U S A. 1990 May;87(10):3967-71
pubmed: 1692628
PLoS One. 2011;6(9):e24566
pubmed: 21931758
Brain Res. 1988 Feb 1;466(2):201-10
pubmed: 3359311
Chem Biol. 1999 Mar;6(3):R65-9
pubmed: 10074470
J Cereb Blood Flow Metab. 2017 Sep;37(9):3203-3218
pubmed: 28058996
J Alzheimers Dis Parkinsonism. 2014 Jan 31;4:
pubmed: 25324979
Acta Neuropathol. 1999 Oct;98(4):396-406
pubmed: 10502046
Mol Cell Neurosci. 2015 May;66(Pt B):91-8
pubmed: 25684677
Mol Biol Cell. 2017 Jan 1;28(1):1-8
pubmed: 28035040
Adv Drug Deliv Rev. 2012 May 15;64(7):614-28
pubmed: 22119441
Pharm Nanotechnol. 2017;5(3):203-214
pubmed: 28521670
J Med Chem. 2014 Jul 24;57(14):6116-27
pubmed: 24992153
J Drug Target. 2009 Feb;17(2):91-7
pubmed: 19089688
Neuroimage. 2004 Dec;23(4):1326-35
pubmed: 15589097
Eur J Nucl Med Mol Imaging. 2004 Jan;31(1):29-37
pubmed: 14551752
Philos Trans R Soc Lond B Biol Sci. 1999 Jul 29;354(1387):1155-63
pubmed: 10466143
J Neurochem. 2015 Jul;134(1):156-72
pubmed: 25712633
J Cereb Blood Flow Metab. 2015 Mar;35(3):371-81
pubmed: 25492117
Mol Cell Neurosci. 2015 May;66(Pt B):81-90
pubmed: 25758552
J Pharm Biomed Anal. 2014 Mar;91:131-7
pubmed: 24447964